We are live on ! Find out more
OCA

Octagon Capital Advisors Portfolio holdings

AUM $904M
1-Year Est. Return 737.04%
This Fund
S&P 500
This Quarter Est. Return
+21.36%
1 Year Est. Return
+737.04%
3 Year Est. Return
+2,554.78%
5 Year Est. Return
+4,333.84%
10 Year Est. Return
–
AUM
$456M
AUM Growth
-$61.2M
Cap. Flow
-$71M
Cap. Flow %
-15.58%
Top 10 Hldgs %
60.57%
Holding
37
New
2
Increased
7
Reduced
12
Closed
7

Top Buys

Rank Stock Value
1
SPRY icon
ARS Pharmaceuticals
SPRY
+$10.5M
2
KYMR icon
Kymera Therapeutics
KYMR
+$9.16M
3
DBVT
DBV Technologies
DBVT
+$9M
4
VRNA
Verona Pharma
VRNA
+$8.87M
5
TSHA icon
Taysha Gene Therapies
TSHA
+$4.11M

Top Sells

Rank Stock Value
1
APLS
Apellis Pharmaceuticals
APLS
+$22M
2
SNDX icon
Syndax Pharmaceuticals
SNDX
+$11.1M
3
SRRK icon
Scholar Rock
SRRK
+$10.6M
4
VSTM icon
Verastem
VSTM
+$10.4M
5
RGLS
Regulus Therapeutics
RGLS
+$8.11M

Sector Composition

Rank Sector Weight
1 Healthcare 99.93%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
DNTH icon
1
Dianthus Therapeutics
DNTH
$5.68B
$43.6M 9.57%
2,341,667
– –
AVBP icon
2
ArriVent BioPharma
AVBP
$1.48B
$42.4M 9.3%
1,946,054
-113,333
-6% -$2.35M
VRNA
3
DELISTED
Verona Pharma
VRNA
$31.9M 7%
337,000
+119,736
+55% +$8.87M
TSHA icon
4
Taysha Gene Therapies
TSHA
$1.59B
$29.1M 6.38%
12,592,500
+1,892,500
+18% +$4.11M
SPRY icon
5
ARS Pharmaceuticals
SPRY
$590M
$23.6M 5.17%
1,350,000
+725,000
+116% +$10.5M
GOSS icon
6
Gossamer Bio
GOSS
$66.5M
$22.6M 4.95%
18,350,000
– –
OCUL icon
7
Ocular Therapeutix
OCUL
$1.86B
$22.5M 4.94%
2,425,000
– –
MRUS
8
DELISTED
Merus
MRUS
$20.5M 4.49%
389,000
+81,000
+26% +$3.81M
TRVI icon
9
Trevi Therapeutics
TRVI
$2.49B
$20.1M 4.41%
3,672,000
+350,000
+11% +$2.18M
COGT icon
10
Cogent Biosciences
COGT
$6.79B
$19.8M 4.35%
2,763,000
– –
ATYR
11
aTyr Pharma
ATYR
$46.4M
$19.4M 4.25%
3,820,000
+268,000
+8% +$1.05M
APLS
12
DELISTED
Apellis Pharmaceuticals
APLS
$15.6M 3.43%
903,500
-1,190,500
-57% -$22M
NUVB icon
13
Nuvation Bio
NUVB
$2.24B
$15M 3.29%
7,691,334
-208,666
-3% -$435K
TRML
14
DELISTED
Tourmaline Bio
TRML
$14.5M 3.18%
905,000
– –
KALV
15
DELISTED
KalVista Pharmaceuticals
KALV
$14.4M 3.16%
1,273,333
-96,667
-7% -$1.18M
DFTX
16
Definium Therapeutics
DFTX
$5.73B
$13.8M 3.03%
2,130,000
-888,000
-29% -$5.84M
CNTA
17
DELISTED
Centessa Pharmaceuticals
CNTA
$13.5M 2.97%
1,030,000
-395,000
-28% -$5M
PHVS icon
18
Pharvaris
PHVS
$2.39B
$11.8M 2.6%
672,595
-97,220
-13% -$1.57M
KYMR icon
19
Kymera Therapeutics
KYMR
$9.1B
$11.6M 2.55%
+266,000
New +$9.16M
ABVX
20
Abivax
ABVX
$11B
$9.69M 2.13%
1,267,000
+37,000
+3% +$241K
DBVT
21
DBV Technologies
DBVT
$807M
$9.31M 2.04%
+1,018,021
New +$9M
CRBP icon
22
Corbus Pharmaceuticals
CRBP
$170M
$7.69M 1.69%
1,115,000
– –
MLTX icon
23
MoonLake Immunotherapeutics
MLTX
$1.59B
$6.99M 1.53%
148,000
-148,000
-50% -$6.03M
UNCY icon
24
Unicycive Therapeutics
UNCY
$148M
$4.77M 1.05%
1,000,000
– –
NGNE icon
25
Neurogene
NGNE
$696M
$4.53M 0.99%
303,000
– –
1
2

Similar funds

AIC
AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return
AOWM
Asset One Wealth Management Bellevue, Washington $904M AUM
SWM
Sendero Wealth Management San Antonio, Texas $904M AUM 22.78% 1-Year Est. Return
EI
EnCap Investments Houston, Texas $905M AUM
PIP
Permian Investment Partners Dallas, Texas $905M AUM 13.43% 1-Year Est. Return
PSCM
Per Stirling Capital Management Austin, Texas $905M AUM 17.06% 1-Year Est. Return
EWM
Evermay Wealth Management Arlington, Virginia $902M AUM 14.76% 1-Year Est. Return
PC
Periscope Capital Toronto, Ontario, Canada $902M AUM 6.51% 1-Year Est. Return

Octagon Capital Advisors's Q2 2025 Portfolio in Review

As of Q2 2025, Octagon Capital Advisors held 37 positions worth $456M, down 12% from $517M the previous quarter. Its ten largest holdings account for 61% of the portfolio.

Octagon Capital Advisors withdrew a net $71M in Q2 2025, closing 7 positions and reducing 12 holdings. Its most notable exit was Syndax Pharmaceuticals, an estimated $11.1M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 89% a quarter earlier.

Against the trend, Octagon Capital Advisors opened a new position in Kymera Therapeutics worth $11.6M.

  • Octagon Capital Advisors's largest Q2 2025 buy was Kymera Therapeutics: 266,000 shares worth $11.6M.
  • Octagon Capital Advisors added most to ARS Pharmaceuticals in Q2 2025, an estimated $10.5M increase.
  • Octagon Capital Advisors's biggest Q2 2025 reduction was Apellis Pharmaceuticals, cutting an estimated $22M.
  • Octagon Capital Advisors fully exited Syndax Pharmaceuticals in Q2 2025, selling an estimated $11.1M.
  • Octagon Capital Advisors's ten largest holdings make up 61% of its $456M portfolio in Q2 2025.
  • Octagon Capital Advisors opened 2 new positions and closed 7 in Q2 2025.
  • Octagon Capital Advisors's portfolio value fell 12% quarter-over-quarter to $456M.

Based on Octagon Capital Advisors's 13F filing for Q2 2025, filed 14 Aug 2025.